Key facts
- It has raised $55.0M; the latest was Seed Round ($25.0M) in Nov 2025.
- Notable investors include K5 Global, Aoki Labs, 9.58 Ventures, David Grutman.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Cymbiotika
- ·The full record, as it builds
Funding rounds
No funding rounds for Cymbiotika are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cymbiotika
Developer of nutritional supplements designed to address nutritional deficiencies and support healthy aging, detoxification, immunity, and longevity. The company offers organic, non-GMO (non-Genetically Modified Organism) formulations with advanced delivery systems such as liposomal technology, enabling health-conscious individuals improved nutrient absorption and overall wellness.
- Sector
- Business Products and Services (B2B)
- HQ
- San Diego, CA, United States
- Founded
- 2018
- Employees
- 101
- Website
- cymbiotika.com/
- Ownership
- Privately Held (backing)
Cymbiotika doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cymbiotika shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cymbiotika in its N-PORT filings yet. We sweep new filings monthly.